Action of Aldosterone on Cultured Renal Collecting Duct Cells during the Latent Period

1990 ◽  
Vol 13 (6) ◽  
pp. 285-294
Author(s):  
Marianne Zwanzig ◽  
Will W. Minuth ◽  
Peter Gross
Keyword(s):  
Latent Period ◽  
Collecting Duct ◽  
Duct Cells ◽  
Collecting Duct Cells ◽  
Renal Collecting Duct

scholarly journals The voltage‐dependent Cl − channel ClC‐5 and plasma membrane Cl − conductances of mouse renal collecting duct cells (mIMCD‐3)

2001 ◽  
Vol 536 (3) ◽  
pp. 769-783 ◽  
Author(s):  
J. A. Sayer ◽  
G. S. Stewart ◽  
S. H. Boese ◽  
M. A. Gray ◽  
S. H. S. Pearce ◽  
...  
Keyword(s):  
Plasma Membrane ◽  
Collecting Duct ◽  
Cl Channel ◽  
Duct Cells ◽  
Voltage Dependent ◽  
Collecting Duct Cells ◽  
Renal Collecting Duct

scholarly journals Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells

2019 ◽  
Vol 21 (1) ◽  
pp. 183
Author(s):  
Annarita Di Mise ◽  
Maria Venneri ◽  
Marianna Ranieri ◽  
Mariangela Centrone ◽  
Lorenzo Pellegrini ◽  
...  
Keyword(s):  
Collecting Duct ◽  
Water Channel ◽  
Plasma Osmolality ◽  
Kinetic Measurements ◽  
Aquaporin 2 ◽  
Plasma Vasopressin ◽  
Duct Cells ◽  
Collecting Duct Cells ◽  
Renal Collecting Duct ◽  
New Generation

Vasopressin V2 receptor (V2R) antagonists (vaptans) are a new generation of diuretics. Compared with classical diuretics, vaptans promote the excretion of retained body water in disorders in which plasma vasopressin concentrations are inappropriately high for any given plasma osmolality. Under these conditions, an aquaretic drug would be preferable over a conventional diuretic. The clinical efficacy of vaptans is in principle due to impaired vasopressin-regulated water reabsorption via the water channel aquaporin-2 (AQP2). Here, the effect of lixivaptan—a novel selective V2R antagonist—on the vasopressin-cAMP/PKA signaling cascade was investigated in mouse renal collecting duct cells expressing AQP2 (MCD4) and the human V2R. Compared to tolvaptan—a selective V2R antagonist indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia—lixivaptan has been predicted to be less likely to cause liver injury. In MCD4 cells, clinically relevant concentrations of lixivaptan (100 nM for 1 h) prevented dDAVP-induced increase of cytosolic cAMP levels and AQP2 phosphorylation at ser-256. Consistent with this finding, real-time fluorescence kinetic measurements demonstrated that lixivaptan prevented dDAVP-induced increase in osmotic water permeability. These data represent the first detailed demonstration of the central role of AQP2 blockade in the aquaretic effect of lixivaptan and suggest that lixivaptan has the potential to become a safe and effective therapy for the treatment of disorders characterized by high plasma vasopressin concentrations and water retention.

Differentiation properties of renal collecting duct cells in culture

1986 ◽  
Vol 33 (2) ◽  
pp. 156-167 ◽  
Author(s):  
Will W. Minuth ◽  
Peter Gilbert ◽  
Günter Lauer ◽  
Klaus Aktories ◽  
Peter Gross
Keyword(s):  
Collecting Duct ◽  
Cells In Culture ◽  
Duct Cells ◽  
Collecting Duct Cells ◽  
Renal Collecting Duct

scholarly journals UropathogenicEscherichia coliAL511 requires flagellum to enter renal collecting duct cells

2009 ◽  
Vol 11 (4) ◽  
pp. 616-628 ◽  
Author(s):  
Christophe Pichon ◽  
Céline Héchard ◽  
Laurence du Merle ◽  
Christelle Chaudray ◽  
Isabelle Bonne ◽  
...  
Keyword(s):  
Collecting Duct ◽  
Duct Cells ◽  
Collecting Duct Cells ◽  
Renal Collecting Duct

scholarly journals microRNA regulation of endothelin-1 mRNA in renal collecting duct cells

Life Sciences ◽  
2014 ◽  
Vol 118 (2) ◽  
pp. 195-199 ◽  
Author(s):  
Mollie E. Jacobs ◽  
Lauren A. Jeffers ◽  
Amanda K. Welch ◽  
Charles S. Wingo ◽  
Brian D. Cain
Keyword(s):  
Collecting Duct ◽  
Microrna Regulation ◽  
Endothelin 1 ◽  
Duct Cells ◽  
Collecting Duct Cells ◽  
Renal Collecting Duct
Sign in / Sign up

Export Citation Format

Share Document